Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

ymphocytic leukemia.

Genzyme took a number of major steps during the second quarter to create opportunities for growth beyond 2011 by significantly strengthening its pipeline and expanding its global infrastructure:

-- The company secured exclusive worldwide rights to mipomersen, an innovative cholesterol-lowering drug in Phase 3 development that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current therapies.

-- Genzyme also formed a collaboration this month with PTC Therapeutics to develop and commercialize PTC124, a novel oral therapy under development initially for Duchenne muscular dystrophy and cystic fibrosis. The product has broad potential in a range of other inherited disorders.

-- Genzyme continued to enroll patients in two ongoing Phase 3 trials of alemtuzumab for the treatment of multiple sclerosis. Final, three-year efficacy and safety data from the Phase 2 trial comparing alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of relapsing-remitting multiple sclerosis were presented during the quarter as part of a scientific platform session at the American Academy of Neurology. The company is awaiting publication of these results.

-- Genzyme announced plans for a research and development center in China and also began building a commercial organization in India, initiatives that reflect the company's commitment to establishing a long-term presence in both countries.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its 2008 earnings guidance; its expectations for approval of Myozyme produced at the 2000L and 4000L-scale capacities, the timing thereof and its assessment of product supply; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD and Clolar for adult AML, the ti
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced the ... & by Products - Global Forecast to 2020" ... market is expected to reach $17.0 Billion in 2020 ... 22.3% during the forecast period of 2015 to 2020 ... availability of a range of products for wide applications, ...
(Date:6/2/2015)... 2015   Hospira, Inc. (NYSE: HSP ... its partner, Celltrion – a global biopharmaceutical company – has ... Agency in Brazil – for ... use in Brazil . The medication ... sells biosimilar infliximab in 26 European countries and in ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 “Stem Cell ... becoming more mainstream, and it is used often as an ... many general practitioners are not yet aware or comfortable enough ... This therapy is most often reserved for the last resort ... poor pet can barely lift a paw to get around. ...
(Date:6/2/2015)... 2, 2015   Intrexon Corporation (NYSE: ... announced today the appointment of Olivier R. ... Sector.  Mr. Jarry will lead the expansion of ... applications for consumer markets.  Mr. ... experience in leading global life sciences and consumer ...
Breaking Biology Technology:Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3
... operate permanently? Can cell phones and tiny robots implanted in ... It might sound like science fiction, but these things seem ... The team of Prof. Keon Jae Lee (KAIST, Dept. of ... Institute of Technology, Dept. of Materials Science and Engineering) has ...
... Federico Rosei of the INRS Energy Materials Telecommunications Center ... 2010 Friedrich Wilhelm Bessel Research Award given by the ... these awards annually to young, high level researchers around ... the caliber and scope of his research in the ...
... Calif., Nov. 11, 2010 Amgen today announced the 11 ... year by the Amgen Foundation, the Awards recognize staff in ... a difference in the communities where the company has a ... organization featured in the winning staff members, applications. ...
Cached Biology Technology:New forms of highly efficient, flexible nanogenerator technology 2INRS professor Federico Rosei receives a 2010 Friedrich Wilhelm Bessel Research Award 2Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits 2Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits 3Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits 4
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... MADISON, WI, JULY 21, 2011 -- Surface water quality ... as well as human needs and recreation. Pasturelands have ... and pathogens in Midwest surface water resources. While poor ... is known about the specific amount of pollution in ...
... program developed by a Penn State synthetic biologist could ... turn bacteria into molecular factories, capable of producing everything ... engineer designs a plane or a car," said Howard ... and chemical engineering. "When designing a biological organism, there ...
... When competing for food and resources, bacteria employ elaborate strategies ... a pathway that allows disease-causing bacteria to attack other bacterial ... aeruginosa is a type of bacteria readily found in ... of settings, including medical devices, body organs and skin wounds. ...
Cached Biology News:Grazing management effects on stream pollutants 2Software helps synthetic biologists customize protein production 2
... is an aqueous solution that contains a ... chemicals in a MOPS buffer (3-(N-Morpholino) propanesulfonic ... product contains a combination of 0.02% methylisothiazolone, ... (Rohm and Haas Company) as a preservative. ...
Request Info...
... Life Science FLA-7000 excels at fluorescent and ... documentation. It features four easy-to-access filters (filters ... filter for Imaging Plates) for upgrading flexibility. ... choice of four kinds of excitation laser ...
... and Labeling Kit generates labeled cDNA for ... cDNA is made via a reverse transcription ... primer. Unlike other methods, there are no ... transcription reaction. This unmodified cDNA is then ...
Biology Products: